Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RenovoRx, Inc. (RNXT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, registration statements, and other documents filed with the U.S. Securities and Exchange Commission. RenovoRx is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform.
Through its SEC filings, RenovoRx reports financial results, commercialization progress for RenovoCath, and updates on its clinical development programs. For example, Form 8‑K filings have referenced quarterly financial press releases that discuss revenue from RenovoCath sales, expansion of cancer center customers, and advancement of the Phase III TIGeR‑PaC trial evaluating intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer.
Filings also describe capital markets activity. In a Form 8‑K dated November 14, 2025, RenovoRx reported entering into a Capital on Demand™ Sales Agreement with a sales agent, allowing the company to issue and sell shares of common stock in at‑the‑market offerings or negotiated transactions under an effective shelf registration statement on Form S‑3. Related exhibits include the sales agreement and a legal opinion on the validity of the shares.
On Stock Titan, users can review these filings alongside AI‑generated highlights that help explain key sections, such as risk factor updates, financing terms, and business strategy disclosures. Investors can also monitor current reports that incorporate press releases detailing clinical milestones, registry studies, Scientific Advisory Board changes, and commercialization strategy for RenovoCath and the TAMP platform.
In addition, this page is a starting point for tracking RenovoRx’s ongoing reporting obligations, including future quarterly and annual reports, as well as any additional Forms 8‑K that may discuss clinical trial developments, capital raises, or changes in governance.
RenovoRx, Inc. filed an amended initial ownership report showing that Chief Financial Officer Mark Voll beneficially owns 25,000 shares of the company’s common stock. These shares are held directly and, according to a footnote, were purchased in open‑market transactions before he became CFO.
RenovoRx, Inc. appointed Ramtin Agah, M.D., its Chief Medical Officer and Board Chairman, to the newly created role of Executive Chairman, effective February 27, 2026. An offer letter dated March 24, 2026 sets his annualized base salary at $450,000 for at least 30 hours per week.
Dr. Agah is eligible for a discretionary annual bonus of up to 40% of his base salary, with the first bonus payable in 2027 for 2026 performance. He may also receive annual stock options and other equity awards under the 2021 Omnibus Equity Incentive Plan, subject to vesting and continued service. His employment is at will and includes customary confidentiality and intellectual property provisions.
RenovoRx director Marton Laurence, through his Laurence Marton Rollover IRA, bought securities in a private placement. The IRA acquired 4,860 warrants and 9,720 shares of RenovoRx common stock for an aggregate purchase price of $10,000.
The warrants are immediately exercisable at $1.9326 per share and will expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter in a quarterly or annual report.
RenovoRx, Inc. director and CEO Shaun Bagai reported indirect purchases through The Bagai Family Trust on March 20, 2026. The trust bought 24,300 shares of common stock and 12,150 warrants in a private placement for an aggregate of $25,000.
After these transactions, the trust holds 313,357 shares of common stock and 12,150 warrants, while Bagai also holds 50,983 shares directly. The warrants are exercisable immediately and can be converted into 12,150 shares of common stock at an exercise price of $1.9326 per share.
The warrants expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter in a quarterly or annual report.
RenovoRx, Inc. Chief Financial Officer Mark Voll, through the Voll Family Trust, reported buying both common stock and warrants in a private placement. The trust acquired 97,200 shares of common stock and 48,600 warrants, for an aggregate purchase price of $100,000.
The warrants are exercisable immediately at $1.9326 per share of underlying common stock and will expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter.
RenovoRx, Inc. filed an initial ownership report for company executive Mark Voll. The filing shows he directly holds 25,000 shares of RenovoRx common stock. A footnote explains these securities were purchased in open-market transactions before his appointment to a senior executive role at the company.
RenovoRx, Inc. entered into a private placement with 15 accredited and institutional investors, including company insiders, raising approximately $10 million in gross proceeds. The company sold 8,438,790 shares of common stock, pre-funded warrants for 2,200,000 shares, and revenue milestone warrants for 5,319,392 shares.
Institutional investors paid $0.938 per share and related milestone warrant, while insiders paid $1.0288 to comply with Nasdaq rules. The milestone warrants are immediately exercisable at $1.751 per share for institutions and $1.9326 for insiders, and expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for a quarter.
RenovoRx agreed to file and seek effectiveness of a resale registration statement for the shares and warrant shares within specified timelines, with cash liquidated damages of up to 10% of each investor’s subscription amount if deadlines are missed. The company plans to use proceeds to support commercialization of its RenovoCath device and advance its Phase III TIGeR-PaC trial.
RenovoRx, Inc. announced leadership changes in its finance organization and highlighted early commercial traction for its RenovoCath device. Principal Accounting Officer Ronald B. Kocak resigned from that role on February 3, 2026, but remains Vice President and Controller with his 2026 salary unchanged.
On February 4, 2026, the board appointed consultant Mark Voll as Chief Financial Officer, serving as the company’s principal financial and accounting officer. Under a consulting agreement, he is paid $250 per hour, half in cash and half in restricted stock units, and is eligible for an initial grant of 60,000 RSUs under the 2021 Omnibus Equity Incentive Plan. A related press release notes that RenovoRx generated approximately $900,000 of RenovoCath sales revenue in the first nine months of 2025 as it transitions from purely clinical-stage activities toward commercialization.
AIGH Capital Management LLC and Orin Hirschman report a 7.1% ownership stake in Renovorx, Inc. common stock on a Schedule 13G/A (Amendment No. 2). They report beneficial ownership of 2,615,193 shares, with sole voting and sole dispositive power over all of these shares and no shared power.
The filing identifies AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman as the reporting persons, with Hirschman serving as managing member and president of the related entities. The securities are certified as acquired and held in the ordinary course of business, and not for the purpose of changing or influencing control of Renovorx.
RenovoRx, Inc. Chief Medical Officer and director Ramtin Agah reported an open market purchase of the company’s common stock. On January 21, 2026, he bought 10,000 shares of RenovoRx common stock in open market transactions at a weighted average price of $0.9975 per share. The filing notes that the shares were acquired in multiple trades at prices ranging from $0.995 to $1.00 per share. Following this purchase, Agah directly holds 798,460 shares of RenovoRx common stock.